Urinary incontinence as a novel and underrecognized clinical manifestation of prolactinoma in women
- PMID: 40884590
- DOI: 10.1007/s11102-025-01567-4
Urinary incontinence as a novel and underrecognized clinical manifestation of prolactinoma in women
Abstract
Objective: Prolactin exerts numerous pleiotropic effects on various tissues, including smooth muscle. Urinary incontinence, particularly the urge subtype, is primarily associated with detrusor overactivity-the involuntary contractions of the bladder's smooth muscle. The aim of this study is to investigate the potential impact of prolactinoma on urinary incontinence (UI) in women.
Methods: This cross-sectional study included 64 patients with prolactinoma and 80 controls. UI was assessed using the International Consultation on Incontinence Questionnaire-Short Form. Based on this instrument, incontinence was categorized into three subtypes: urge urinary incontinence (UUI), stress urinary incontinence (SUI), and mixed urinary incontinence (MUI).
Results: The overall rate of UI was significantly higher in prolactinoma patients, with 20 cases (31.3%), compared to 6 cases (7.5%) in the control group (p < 0.001). Compared to the control group, prolactinoma patients exhibited higher rates of UUI and MUI, while no difference was found in SUI rates (p = 0.012, p = 0.008, and p = 0.839; respectively). Incontinent patients had a higher mean age, a greater frequency of macroadenoma, and a longer disease duration compared to continent patients (p = 0.015, p = 0.038, and p < 0.001; respectively). The logistic regression analysis suggested that the disease duration was the only independent predictor of UI in the prolactinoma patients.
Conclusion: Prolactinoma, particularly in the later stages of the disease, may influence detrusor muscle activity in female patients and contribute to an increased prevalence of UI.
Keywords: Prolactin; Prolactinoma; Stress incontinence; Urge incontinence; Urinary incontinence.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by “Scientific Research Assessment and Ethics Committee of Ankara Etlik City Hospital” (Date: 13/05/2025 No: AEŞH-BADEK2-2025-095). Consent to participate: Informed consent was obtained from participants. Financial interests: The authors declare they have no financial interests. Competing interests: The authors declare no competing interests.
Similar articles
-
Conservative interventions for treating urinary incontinence in women: an Overview of Cochrane systematic reviews.Cochrane Database Syst Rev. 2022 Sep 2;9(9):CD012337. doi: 10.1002/14651858.CD012337.pub2. Cochrane Database Syst Rev. 2022. PMID: 36053030 Free PMC article.
-
Vaginal lasers for treating stress urinary incontinence in women.Cochrane Database Syst Rev. 2025 Jul 25;7(7):CD013643. doi: 10.1002/14651858.CD013643.pub2. Cochrane Database Syst Rev. 2025. PMID: 40709601 Review.
-
Relationship between the weight-adjusted-waist index and urinary incontinence in women: A cross-sectional study of NHANES 2007 to 2020.Medicine (Baltimore). 2025 Jun 20;104(25):e42996. doi: 10.1097/MD.0000000000042996. Medicine (Baltimore). 2025. PMID: 40550030 Free PMC article.
-
Economic burden of urgency urinary incontinence in the United States: a systematic review.J Manag Care Pharm. 2014 Feb;20(2):130-40. doi: 10.18553/jmcp.2014.20.2.130. J Manag Care Pharm. 2014. PMID: 24456314 Free PMC article.
-
Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.Cochrane Database Syst Rev. 2015 Nov 3;2015(11):CD010551. doi: 10.1002/14651858.CD010551.pub3. Cochrane Database Syst Rev. 2015. PMID: 26526663 Free PMC article.
References
-
- Auriemma RS, Pirchio R, Pivonello C et al (2023) Approach to the patient with prolactinoma. J Clin Endocrinol Metab 108:2400–2423. https://doi.org/10.1210/clinem/dgad174 - DOI - PubMed - PMC
-
- Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8:3–6. https://doi.org/10.1007/s11102-005-5079-0 - DOI - PubMed
-
- Kars M, Souverein PC, Herings RMC et al (2009) Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94:2729–2734. https://doi.org/10.1210/jc.2009-0177 - DOI - PubMed
-
- Vroonen L, Daly AF, Beckers A (2019) Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109:20–27. https://doi.org/10.1159/000497746 - DOI - PubMed
-
- Tritos NA, Miller KK (2023) Diagnosis and management of pituitary adenomas. JAMA 329:1386. https://doi.org/10.1001/jama.2023.5444 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical